ATX and INNMF Related Headlines
Go Back- Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
- Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
- Accent Trial Mature Data Presented at International Conference
- Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
- Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
- Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium
- Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors
- Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th
- Life Science Virtual Investor Forum Agenda Announced for September 18th
ATX and INNMF Related Press Releases
Go Back- Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
- Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
- Accent Trial Mature Data Presented at International Conference
- Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
- Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
- Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium
- Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors
- Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th
- Life Science Virtual Investor Forum Agenda Announced for September 18th
